Femasys (NASDAQ:FEMY) CEO Purchases $50,000.00 in Stock

Femasys Inc. (NASDAQ:FEMY) CEO Kathy Lee-Sepsick bought 15,625 shares of the business’s stock in a transaction on Friday, August 7th. The shares were acquired at an average cost of $3.20 per share, for a total transaction of $50,000.00. Following the purchase, the chief executive officer directly owned 15,625 shares in the company, valued at $50,000. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Femasys Stock Performance

Shares of NASDAQ:FEMY traded down $0.02 on Tuesday, hitting $2.35. The company’s stock had a trading volume of 228,436 shares, compared to its average volume of 120,035. Femasys Inc. has a 12 month low of $2.29 and a 12 month high of $22.20. The company has a market capitalization of $7.10 million, a price-to-earnings ratio of -0.44 and a beta of -2.08. The stock’s 50-day moving average is $3.87 and its two-hundred day moving average is $7.49. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.98 and a current ratio of 3.91.

Femasys (NASDAQ:FEMY) last issued its quarterly earnings data on Friday, May 8th. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.33) by $1.43. The business had revenue of $0.42 million for the quarter, compared to analysts’ expectations of $0.77 million. Femasys had a negative net margin of 521.97% and a negative return on equity of 258.08%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Weiss Ratings upgraded shares of Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 31st. Wall Street Zen upgraded Femasys to a “hold” rating in a research report on Saturday, June 13th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Femasys presently has an average rating of “Hold” and a consensus target price of $80.00.

Institutional Investors Weigh In On Femasys

Institutional investors and hedge funds have recently bought and sold shares of the business. State Street Corp grew its stake in shares of Femasys by 43.5% in the 4th quarter. State Street Corp now owns 80,869 shares of the company’s stock worth $47,000 after purchasing an additional 24,500 shares during the last quarter. Kovack Advisors Inc. bought a new stake in Femasys during the fourth quarter worth approximately $27,000. Osaic Holdings Inc. bought a new stake in Femasys during the second quarter worth approximately $45,000. HRT Financial LP acquired a new position in Femasys in the fourth quarter worth approximately $30,000. Finally, Cetera Investment Advisers acquired a new position in Femasys in the fourth quarter worth approximately $36,000. 65.27% of the stock is owned by institutional investors and hedge funds.

Femasys Company Profile

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.